A review of the pharmacokinetics and pharmacodynamics of remifentanil

Anesthesia and Analgesia

Volumn 89, Issue 4 SUPPL., 1999, Pages

  Glass, Peter S A ^a   Gan, Tong J ^a   Howell, Scott ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; FENTANYL; ISOFLURANE; NITROUS OXIDE; PROPOFOL; REMIFENTANIL; SUFENTANIL; THIOPENTAL;

ANESTHESIA INDUCTION; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; HUMAN; MINIMUM LUNG ALVEOLUS CONCENTRATION; PRIORITY JOURNAL; REVIEW;

EID: 0032832675     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000539-199910001-00003     Document Type: Review

References (30)

1. James MK, Vuong A, Grizzle MK, et al. Hemodynamic effects of GI87084B, an ultra-short acting mu-opioid analgesic, in anesthetized dogs. J Pharmacol Exp Ther 1992;263:84-91.
2. James MK, Feldman PI, Schuster SV, et al. Opioid receptor activity of GI87084B, a novel ultra-short acting analgesic, in isolated tissues. J Pharmacol Exp Ther 1991;259:712-8.
3. Amin HM, Sopchak AM, Esposito BF, et al. Naloxone-induced and spontaneous reversal of depressed ventilatory responses to hypoxia during and after continuous infusion of remifentanil and alfentanil. J Pharmacol Exp Ther 1995;274:34-9.
4. Egan TD, Lemmens HJM, Fiset P, et al. The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers. Anesthesiology 1993;79:881-92.
5. Glass PSA, Hardman D, Kamiyama Y, et al. Preliminary pharmacokinetics and pharmacodynamics of an ultra-short-acting opioid: remifentanil (GI87084B). Anesth Analg 1993;77:1031-40.
6. Westmoreland CL, Hoke JF, Sebel PS, et al. Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. Anesthesiology 1993;79:893-903.
7. Hoffman WE, Cunningham F, James MK, et al. Effects of remifentanil, a new short-acting opioid, on cerebral blood flow, brain electrical activity, and intracranial pressure in dogs anesthetized with isoflurane and nitrous oxide. Anesthesiology 1993;79:107-13.
8. Stiller RL, Davis PJ, McGowan FX, et al. In vitro metabolism of remifentanil: the effects of pseudocholinesterase deficiency [abstract], Anesthesiology 1995;83:A381.
9. Hoke JF, Cunningham F, James MK, et al. Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. J Pharmacol Exp Ther 1997;281:226-32.
10. Kapila A, Glass PSA, Jacobs JR, et al. Measured context-sensitive half times of remifentanil and alfentanil. Anesthesiology 1995; 83:968-75.
11. Dershwitz M, Randel GI, Rosow CE, et al. Initial clinical experience with remifentanil, a new opioid metabolized by esterases. Anesth Analg 1995;81:619-23.
12. Dershwitz M, Hoke JF, Rosow CE, Michalowski P. Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease. Anesthesiology 1996;84: 812-20.
13. Hoke JF, Dershwitz M, Glass PSA, et al. Pharmacokinetics and pharmacodynamics of remifentanil in subjects with renal failure compared to healthy volunteers. Anesthesiology 1997;87: 531-41.
14. Duthie DJR, Muir KT, Baddoo HHK, et al. Remifentanil is not metabolized by the lung [abstract]. Anesthesiology 1995;83: A324.
15. Davis PJ, Ross A, Stiller RL, et al. Pharmacokinetics of remifentanil in anesthetized children 2-12 years of age [abstract]. Anesth Analg 1995;80:S93.
16. Minto CF, Schnider TW, Egan TD. Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. Anesthesiology 1997;86:10-23.
17. Hughes SC, Kan RE, Rosen MA, et al. Remifentanil: ultra-short acting opioid for obstetric anesthesia [abstract]. Anesthesiology 1996;85:A894.
18. Glass PSA, Shafer SL, Jacobs JR, Reves JG. Intravenous drug delivery systems. In: Miller R, ed. Anesthesia. 4th ed. New York: Churchill Livingstone, 1994:389-416.
19. Jhaveri R, Joshi P, Batenhorst R, et al. Dose comparison of remifentanil and alfentanil for loss of consciousness. Anesthesiology 1997;87:253-9.
20. Ausems ME, Vuyk J, Hug CC Jr, Stanski DR. Comparison of a computer-assisted infusion versus intermittent bolus administration of alfentanil as a supplement to nitrous oxide for lower abdominal surgery. Anesthesiology 1988;68:851-61.
21. Glass PSA, Doherty M, Jacobs JR, et al. Plasma concentration of fentanyl, with 70% nitrous oxide, to prevent movement at skin incision. Anesthesiology 1993;78:842-7.
22. Egan TD, Minto CF, Hermann DJ, et al. Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers. Anesthesiology 1996; 84:821-33.
23. Lang E, Kapila A, Shlugman D, et al. Reduction of isoflurane minimal alveolar concentration by remifentanil. Anesthesiology 1996;54:721-8.
24. McEwan AI, Smith C, Dyar O, et al. Isoflurane MAC reduction by fentanyl. Anesthesiology 1993;78:864-9.
25. Brunner MD, Braithwaite P, Jhaveri R, et al. The MAC reduction of isoflurane by sufentanil. Br J Anaesth 1994;72:42-6.
26. Westmoreland CL, Sebel PS, Cropper A. Fentanyl of alfentanil decreases the minimum alveolar anesthetic concentration of isoflurane in surgical patients. Anesth Analg 1994;78:23-8.
27. Hogue CW Jr, Bowdle TA, O'Leary C, et al. Multicenter evaluation of total intravenous anesthesia with remifentanil and propofol for elective inpatient surgery. Anesth Analg 1996;83: 279-85.
28. Sebel PS, Hoke JF, Westmoreland C, et al. Histamine concentrations and hemodynamic responses after remifentanil. Anesth Analg 1995;80:990-3.
29. Warner DS, Hindman BJ, Todd MM, et al. Intracranial pressure and hemodynamic effects of remifentanil versus alfentanil in patients undergoing supratentorial craniotomy. Anesth Analg 1996;83:348-53.
30. Vuyk J, Mertens MJ, Olofsen E, Bovill JG. Opioid selection affects the optimal propofol concentration that assures both adequate anesthesia and a rapid recovery [abstract]. Anesthesiology 1996;85:A345.